InsiderSignalSign in

← Insider buys

Michael Raab has sold stock and made no open-market buys since Oct 2017

President and CEO at Ardelyx, Inc., and 1 other company

SEC CIK 0001321402 · Filings on SEC.gov ↗

$0Bought

$7.2MSold

NoneLast buy

Companies

Every filing

46 filings since Oct 2017, newest first

ARDELYX, INC.

President and CEO

$226K−3.5%Aug 25

ARDELYX, INC.

President and CEO

$211K−2.4%Jul 17

ARDELYX, INC.

President and CEO

$236K−2.4%Jun 17

Ardelyx, Inc.

President and CEO

$343K−3.0%May 22

Ardelyx, Inc.

President and CEO

$262K−2.0%May 19

Ardelyx, Inc.

President and CEO

$262K−2.0%Apr 17

Ardelyx, Inc.

President and CEO

$243K−2.0%Mar 18

Ardelyx, Inc.

President and CEO

$261K−2.0%Feb 25

Ardelyx, Inc.

President and CEO

$269K−2.0%Feb 23

Ardelyx, Inc.

President and CEO

$260K−3.0%Nov 25

Ardelyx, Inc.

President and CEO

$134K−2.0%Nov 27

Ardelyx, Inc.

President and CEO

$153K−3.0%Nov 22

Ardelyx, Inc.

President and CEO

$148K−2.0%Oct 31

Ardelyx, Inc.

President and CEO

$45K−1.0%Oct 15

Ardelyx, Inc.

President and CEO

$196K−3.0%Sep 13

Ardelyx, Inc.

President and CEO

$47K−1.0%Aug 28

Ardelyx, Inc.

President and CEO

$189K−3.0%Aug 22

Ardelyx, Inc.

President and CEO

$169K−2.0%Jul 31

Ardelyx, Inc.

President and CEO

$45K−1.0%Jul 17

Ardelyx, Inc.

President and CEO

$233K−3.0%Jun 17

Ardelyx, Inc.

President and CEO

$50K−1.0%May 31

Ardelyx, Inc.

President and CEO

$246K−2.0%May 23

Ardelyx, Inc.

President and CEO

$192K−2.0%May 1

Ardelyx, Inc.

President and CEO

$53K−1.0%Apr 17

Ardelyx, Inc.

President and CEO

$200K−2.0%Feb 22

Ardelyx, Inc.

President and CEO

$50K−1.0%Nov 22

Ardelyx, Inc.

President and CEO

$41K−1.0%Aug 23

Ardelyx, Inc.

President and CEO

$41K−1.0%May 25

Amicus Therapeutics, Inc.

Director

$50K−7.0%Mar 21

Ardelyx, Inc.

President and CEO

$40K−1.0%Feb 24

Ardelyx, Inc.

President and CEO

$67K−13.0%Jun 8

Amicus Therapeutics, Inc.

Director

$105K−29.0%May 4

Ardelyx, Inc.

President and CEO

$596K−45.0%Sep 17

Ardelyx, Inc.

President and CEO

$162K−9.0%Jul 6

Amicus Therapeutics, Inc.

Director

$63K−25.0%Jun 3

Ardelyx, Inc.

President and CEO

$170K−8.0%Jun 2

Ardelyx, Inc.

President and CEO

$143K−7.0%May 5

Ardelyx, Inc.

President and CEO

$143K−6.0%Apr 17

Ardelyx, Inc.

President and CEO

$221K−9.0%Mar 4

Ardelyx, Inc.

President and CEO

$183K−7.0%Feb 7

Ardelyx, Inc.

President and CEO

$26K−3.0%Jun 6

Amicus Therapeutics, Inc.

Director

$56K−36.0%Jun 4

Ardelyx, Inc.

President and CEO

$33K−5.0%Jan 4

Amicus Therapeutics Inc

Director

$72K−46.0%Apr 18

Amicus Therapeutics Inc

Director

$140K−62.0%Jan 4

Amicus Therapeutics Inc

Director

$143K−63.0%Oct 16

About Michael Raab

Michael G. Raab is a Person and serves as President and Chief Executive Officer of Ardelyx, Inc. (NASDAQ: ARDX), a role he has held since 2009.( In that capacity, he has led the company through key milestones, including the FDA approval of XPHOZAH, and he also appears in recent insider-trading filings tied to Ardelyx stock transactions.(

Before joining Ardelyx, Raab was a partner at New Enterprise Associates (NEA) and spent about 15 years in commercial and operating leadership roles across biotechnology and pharmaceuticals, including senior vice president, therapeutics and general manager of the Renal Division at Genzyme, as well as earlier roles in Genzyme’s diagnostic products and services division, and business development and sales and marketing positions at Repligen and Bristol-Myers.( He earned a Bachelor of Arts in Communication from DePauw University.(

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.